TG Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 9, 2022 and accepted by EDGAR at Aug 9, 2022, 16:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-04-01 to 2022-06-30 | $26.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-01-01 to 2022-06-30 | $74.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-04-01 to 2022-06-30 | $12.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-01-01 to 2022-06-30 | $33.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$38.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$105.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-04-01 to 2022-06-30 | $3.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2022-01-01 to 2022-06-30 | $5.7m | us-gaap:InterestExpense |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$109.5m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | −$0.30 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | −$0.81 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$0.30 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$0.81 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 134,779,904 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 134,591,250 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$117.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $7.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-06-30 | $147.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $202.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $251.7m | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $43.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $122.6m | us-gaap:Liabilities |
| Long-term debt | At period end2022-06-30 | $68.9m | us-gaap:LongTermDebtNoncurrent |
Source: SEC EDGAR, the filing index for accession 0001558370-22-012854. Last ingested by Listed: Oct 24, 2026, 15:01 ET. Listed shows no prices and gives no investment advice.